Genmab A (GMAB) Other Non-Current Assets (2025 - 2026)

Genmab A (GMAB) posted Other Non-Current Assets of $22.0 million for Q1 2026, little changed on a QoQ basis from $22.0 million in Q4 2025.

Genmab A (GMAB) Other Non-Current Assets (2025 - 2026) Analysis & Trends

Genmab A's Other Non-Current Assets history runs 2 years deep, the most recent figure standing at $22.0 million for Q1 2026.

Quarterly Other Non-Current Assets changed N/A year-over-year to $22.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.0 million (changed N/A YoY) and the FY2025 annual result came in at $22.0 million, changed N/A from the prior year.
Other Non-Current Assets was $22.0 million for Q1 2026 at Genmab A, roughly flat from $22.0 million in the prior quarter.
Across five years, Other Non-Current Assets topped out at $22.0 million in Q4 2025 and bottomed at $9.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	1.02 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	104.24 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	1.26 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	2.13 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	289.41 Mn
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	124.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	14.48 Mn
10	Genmab A	1.89 Bn	366.92 Mn	831.00 Mn	22.00 Mn

Download Data